Beware the hype but a deal with one of the big oncology players that involves $96m upfront and potentially $5.0bn in milestones is a decent validation for the German biotech's technology platform.
Affimed NV has inked a deal with Roche's Genentech unit which could be worth billions of dollars and make the German biotech a major player in the next wave of immuno-oncology.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
Adstiladrin sales hit €70m in first full year on the market
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
